INmune Bio Inc. Presents Data on INB03's Role as an Immune C

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca Raton, Florida, April 08,...

Related Keywords

Boca Raton , Florida , United States , American , David Moss , Roxana Schillaci , Gil Deza , Jason Nelson , Cordo Russo , Maria Florencia Mercogliano , Inmune Bio , Joshua Schoonover , Company Annual Report On Form , Exchange Commission , Inmune Bio Inc , Company Current Reports On Form , Nasdaq , American Association Of Cancer Research , Drug Administration , Company Quarterly Reports On Form , Dupont , Overcome Resistance , Enhance Therapeutic Outcome , High Risk Breast , American Association , Cancer Research , San Diego , Inhibitory Molecules , Sofia Bruni , Expression Differences , Metastatic Progression , Lopez Della Vecchia , General Counsel , Dominant Negative Tumor Necrosis Factor , Mild Alzheimer , Mild Cognitive Impairment , Natural Killer Cell Priming Platform , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Bio Contact ,